The company said that the new test would cut the number of volunteers required for trials by 50%, reducing recruitment times and project management costs, and that when combined with human volunteers Labskin would allow for double the number of possible skin tests and make them more reliable and accurate.
The Labskin artificial intelligence (AI) platform would allow clients to receive real-time feedback, Integumen said.
Labskin, much like the name suggests, is laboratory-grown skin that is then used by cosmetic and pharmaceutical companies to test how their products react to human skin.
Gerard Brandon, Integumen’s chief executive, said the new Labskin test would “enhance the margins of medical device and clinical trial organisations on test subjects” and deliver “faster, more reliable and consistent results for their skin care, health care, wound care and pharmaceutical clients” at a lower cost.
In early afternoon, the company’s shares were up 16.4% at 1.9p.